Pharma Exclusives Pressreleases
BioMed X and Servier Launch First XSeed Labs in Europe
Wednesday, July 09, 2025BioMed X an independent biomedical research institute based in Heidelberg Germany announced today the launch of a new initiative with Servier The two partners will implement BioMed Xs proven XSeed Labs incubator model at Serviers
Ofichem acquires Avivia B.V. to expand formulation development capabilities
Wednesday, July 09, 2025Ofichem Group has signed a definitive agreement to acquire Avivia BV a company specialized in formulation development based in Nijmegen the Netherlands
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
Monday, July 07, 2025HeartBeatbio AG and biotxai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure The collaboration combines biotxais causal mapping
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Thursday, July 03, 2025Neurizon Therapeutics Limited a clinicalstage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases is pleased to announce it has executed an exclusive global license
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Monday, June 30, 2025Hansa Biopharma AB Hansa announced today the presentation of its five year extended pooled analysis including data from the HMedIdeS study an international longterm followup study of patients who have received
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder
Friday, June 27, 2025UCB a global biopharmaceutical company today announced that the phase study investigating the safety and efficacy of adjunctive fenfluramine in CDKL Deficiency Disorder CDD met its primary and key secondary endpoints
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Friday, June 27, 2025Vetter a leading globally operating Contract Development and Manufacturing Organization CDMO celebrated the start of construction for its new clinical manufacturing site in Des Plaines with an official groundbreaking ceremony
Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Tuesday, June 24, 2025Novo Nordisk today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion for an update of the Ozempic
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
Monday, June 23, 2025Novo Nordisk today presented results from the phase b FRONTIER trial showing that a direct switch to investigational Mim denecimig prophylaxis from emicizumab treatment without a washout period
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Monday, June 23, 2025Roche announced today positive phase III data on NXT in people with haemophilia A supporting its progression into phase III clinical development NXT is a nextgeneration investigational bispecific antibody
